270 related articles for article (PubMed ID: 31271486)
21. Nucleolar translocation of human DNA topoisomerase II by ATP depletion and its disruption by the RNA polymerase I inhibitor BMH-21.
Morotomi-Yano K; Yano KI
Sci Rep; 2021 Nov; 11(1):21533. PubMed ID: 34728715
[TBL] [Abstract][Full Text] [Related]
22. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
23. The Aza-Analogous Benzo[
Aichinger G; Lichtenberger FB; Steinhauer TN; Flörkemeier I; Del Favero G; Clement B; Marko D
Molecules; 2020 Mar; 25(7):. PubMed ID: 32230817
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells.
Bandele OJ; Osheroff N
Biochemistry; 2008 Nov; 47(45):11900-8. PubMed ID: 18922022
[TBL] [Abstract][Full Text] [Related]
25. RAD54L2-mediated DNA damage avoidance pathway specifically preserves genome integrity in response to topoisomerase 2 poisons.
Zhang H; Xiong Y; Sun Y; Park JM; Su D; Feng X; Keast S; Tang M; Huang M; Wang C; Srivastava M; Yang C; Zhu D; Chen Z; Li S; Yin L; Pommier Y; Chen J
Sci Adv; 2023 Dec; 9(49):eadi6681. PubMed ID: 38055811
[TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms.
Van Ravenstein SX; Mehta KP; Kavlashvili T; Byl JAW; Zhao R; Osheroff N; Cortez D; Dewar JM
EMBO J; 2022 Jun; 41(12):e110632. PubMed ID: 35578785
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.
Riccio AA; Schellenberg MJ; Williams RS
Cell Mol Life Sci; 2020 Jan; 77(1):81-91. PubMed ID: 31728578
[TBL] [Abstract][Full Text] [Related]
28. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
29. SUMO-Targeted DNA Translocase Rrp2 Protects the Genome from Top2-Induced DNA Damage.
Wei Y; Diao LX; Lu S; Wang HT; Suo F; Dong MQ; Du LL
Mol Cell; 2017 Jun; 66(5):581-596.e6. PubMed ID: 28552615
[TBL] [Abstract][Full Text] [Related]
30. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
[TBL] [Abstract][Full Text] [Related]
31. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
[TBL] [Abstract][Full Text] [Related]
32. Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187.
Wang L; Eastmond DA
Environ Mol Mutagen; 2002; 39(4):348-56. PubMed ID: 12112387
[TBL] [Abstract][Full Text] [Related]
33. HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and β.
Wilson JT; Fief CA; Jackson KD; Mercer SL; Deweese JE
Chem Res Toxicol; 2018 Feb; 31(2):137-144. PubMed ID: 29272108
[TBL] [Abstract][Full Text] [Related]
34. ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Bian K; Muppani NR; Elkhadragy L; Wang W; Zhang C; Chen T; Jung S; Seternes OM; Long W
Oncotarget; 2016 Feb; 7(6):6665-75. PubMed ID: 26701725
[TBL] [Abstract][Full Text] [Related]
35. MYC assembles and stimulates topoisomerases 1 and 2 in a "topoisome".
Das SK; Kuzin V; Cameron DP; Sanford S; Jha RK; Nie Z; Rosello MT; Holewinski R; Andresson T; Wisniewski J; Natsume T; Price DH; Lewis BA; Kouzine F; Levens D; Baranello L
Mol Cell; 2022 Jan; 82(1):140-158.e12. PubMed ID: 34890565
[TBL] [Abstract][Full Text] [Related]
36. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Saraiya B; Gounder M; Dutta J; Saleem A; Collazo C; Zimmerman L; Nazar A; Gharibo M; Schaar D; Lin Y; Shih W; Aisner J; Strair RK; Rubin EH
Anticancer Drugs; 2008 Apr; 19(4):411-20. PubMed ID: 18454051
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase IIα represses transcription by enforcing promoter-proximal pausing.
Herrero-Ruiz A; Martínez-García PM; Terrón-Bautista J; Millán-Zambrano G; Lieberman JA; Jimeno-González S; Cortés-Ledesma F
Cell Rep; 2021 Apr; 35(2):108977. PubMed ID: 33852840
[TBL] [Abstract][Full Text] [Related]
38. NEK5 interacts with topoisomerase IIβ and is involved in the DNA damage response induced by etoposide.
Melo-Hanchuk TD; Slepicka PF; Pelegrini AL; Menck CFM; Kobarg J
J Cell Biochem; 2019 Oct; 120(10):16853-16866. PubMed ID: 31090963
[TBL] [Abstract][Full Text] [Related]
39. Dominant lethal mutations of topoisomerase II inhibitors etoposide and merbarone in male mice: a mechanistic study.
Attia SM
Arch Toxicol; 2012 May; 86(5):725-31. PubMed ID: 22207148
[TBL] [Abstract][Full Text] [Related]
40. The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison.
Cowell IG; Ling EM; Swan RL; Brooks MLW; Austin CA
Mol Pharmacol; 2019 Nov; 96(5):562-572. PubMed ID: 31515282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
